David Martin PhD
Stock Analyst at Bloom Burton
(4.65)
# 821
Out of 4,408 analysts
219
Total ratings
49.2%
Success rate
16.4%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSXV: RX BioSyent Inc. | Maintained: Buy | $16.50 → $18.00 | $13.95 | +29.03% | 14 | Jun 4, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Maintained: Buy | $12.00 | $4.24 | +183.02% | 50 | May 19, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Maintained: Buy | $0.50 → $0.40 | $0.29 | +37.93% | 13 | May 15, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 | $16.00 | -6.25% | 33 | May 11, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $11.00 → $12.00 | $9.48 | +26.58% | 28 | May 8, 2026 | |
| TSX: CRRX CareRx Corporation | Maintained: Buy | $5.50 → $5.00 | $3.15 | +58.73% | 11 | May 8, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $35 | $23.26 | +50.47% | 12 | Apr 27, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $19.56 | $8.72 | +124.35% | 5 | Apr 27, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Maintained: Buy | $4.00 → $5.00 | $1.25 | +300.00% | 3 | Mar 19, 2026 | |
| XENE Xenon Pharmaceuticals | Maintained: Buy | $57 → $74 | $52.40 | +41.22% | 8 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $4.25 | +1,005.88% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6.00 | $4.18 | +43.54% | 12 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.38 → $4.00 | $0.415 | +863.86% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $5.26 | +71.10% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $16.30 | -13.51% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.20 → $19.00 | $18.59 | +2.21% | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1.00 | $0.255 | +292.16% | 2 | Jul 6, 2025 |
BioSyent Inc.
Jun 4, 2026
Maintained: Buy
Price Target: $16.50 → $18.00
Current: $13.95
Upside: +29.03%
HLS Therapeutics Inc.
May 19, 2026
Maintained: Buy
Price Target: $12.00
Current: $4.24
Upside: +183.02%
Microbix Biosystems Inc.
May 15, 2026
Maintained: Buy
Price Target: $0.50 → $0.40
Current: $0.29
Upside: +37.93%
Aurinia Pharmaceuticals
May 11, 2026
Maintained: Hold
Price Target: $15
Current: $16.00
Upside: -6.25%
Knight Therapeutics Inc.
May 8, 2026
Maintained: Buy
Price Target: $11.00 → $12.00
Current: $9.48
Upside: +26.58%
CareRx Corporation
May 8, 2026
Maintained: Buy
Price Target: $5.50 → $5.00
Current: $3.15
Upside: +58.73%
Zymeworks
Apr 27, 2026
Maintained: Buy
Price Target: $35
Current: $23.26
Upside: +50.47%
Eupraxia Pharmaceuticals Inc.
Apr 27, 2026
Maintained: Buy
Price Target: $19.56
Current: $8.72
Upside: +124.35%
PYC Therapeutics Limited
Mar 19, 2026
Maintained: Buy
Price Target: $4.00 → $5.00
Current: $1.25
Upside: +300.00%
Xenon Pharmaceuticals
Mar 9, 2026
Maintained: Buy
Price Target: $57 → $74
Current: $52.40
Upside: +41.22%
Mar 5, 2026
Maintained: Buy
Price Target: $47
Current: $4.25
Upside: +1,005.88%
Feb 13, 2026
Maintained: Buy
Price Target: $6.00
Current: $4.18
Upside: +43.54%
Dec 11, 2025
Maintained: Buy
Price Target: $8.38 → $4.00
Current: $0.415
Upside: +863.86%
Nov 19, 2025
Maintained: Buy
Price Target: $9
Current: $5.26
Upside: +71.10%
Oct 21, 2025
Maintained: Buy
Price Target: $14
Current: $16.30
Upside: -13.51%
Jul 18, 2025
Maintained: Buy
Price Target: $20.20 → $19.00
Current: $18.59
Upside: +2.21%
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1.00
Current: $0.255
Upside: +292.16%